基于真实世界数据胸腺法新用于病毒性肺炎的用药合理性分析以及疗效评价  

Reasonableness analysis and efficacy evaluation of thymalfasin for viral pneumonia based on real-world data

作　　者：张歆 李欢欢 马祖文[1] 张裴[1] ZHANG Xin;LI Huan-huan;MA Zu-wen(Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China.)

机构地区：[1]新疆医科大学第五附属医院,乌鲁木齐830000

出　　处：《中国处方药》2024年第4期66-69,共4页Journal of China Prescription Drug

基　　金：新疆维吾尔自治区自然科学基金项目(2022D01C581)。

摘　　要：目的基于真实世界数据,分析某院注射用胸腺法新的使用情况,探讨其用于病毒性肺炎防治的合理性,以期为胸腺肽类药物的临床合理用药提供参考。方法采用回顾性研究法,收集某院2022年12月~2023年3月使用胸腺法新的病例进行全样本点评,从用药指征、用药时机、用法用量、用药疗程等方面评价其合理性,随访预后,评价疗效。结果共纳入174例患者,>65岁以上的老人占比达80.46%,住院天数大多在7~14 d,呼吸科和ICU患者占比最大,主要诊断为新冠病毒感染、重症肺炎、脓毒血症等,多数病例合并多种疾病,经点评,注射用胸腺法新适应证不合理率为24.14%;给药剂量不适宜比例为12.10%,给药途径不适宜比例为2.63%,溶媒不适宜比例为12.89%。结论真实世界数据提示,注射用胸腺法新存在不合理使用情况,对于免疫力低下的COVID-19重症患者具有一定疗效,建议COVID-19患者用药时严格把握胸腺法新的使用指征及使用时机,谨慎用药。Objective Based on real-world data,to analyze the use condition of thymalfasin injection in a hospital,and to explore its rationality in the prevention and treatment of viral pneumonia,in order to provide reference for the clinical rational use of thymic peptide drugs.Methods A retrospective study method was used to collect cases of thymalfasin used in a hospital from December 2022 to March 2023 for a full sample review.The rationality was evaluated from the aspects of medication indications,timing,dosage and course of treatment,the prognosis was followed up,the efficacy was evaluated.Results A total of 174 patients were included,80.46%of them were older than 65 years old,and most of them were hospitalized for 7~14 days.Respiratory department and ICU patients accounted for the largest proportion,mainly diagnosed as COVID-19 infec�tion,severe pneumonia,sepsis,etc.Most cases were complicated with multiple diseases,after comments,the unreasonable rate of indications for thymalfasin injection was 24.14%;the proportion of unsuitable dosage was 12.10%,the proportion of unsuitable route of administration was 2.63%,and the proportion of unsuitable solvent was 12.89%.Conclusion Real-world data suggests that there is an unreasonable use of thymalfasin,which has certain therapeutic effects on COVID-19 critically ill patients with weakened immunity.It is recommended that COVID-19 patients strictly grasp the indications and timing of thymalfasin use,and use medication with caution.

关 键 词：胸腺法新 病毒性肺炎 新冠病毒感染 合理用药 疗效评价 

分 类 号：R969[医药卫生—药理学] R563.1[医药卫生—药学]